Clinical Trial Update: A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating Eisai's investigational anti-tau agent E2814 for safety and target engagement in individuals with mild to moderate cognitive impair…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• E2814

Snippet

Sponsor: Eisai Inc. | Conditions: Alzheimer Disease | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-06-10